Cogent Biosciences Stock Forecast, Price & News

Cogent Biosciences' stock was trading at $0.3736 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, UMRX shares have increased by 2,525.8% and is now trading at $9.81.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cogent Biosciences or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Cogent Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cogent Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Cogent Biosciences, Inc. (NASDAQ:UMRX) posted its earnings results on Tuesday, August, 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.03. The business had revenue of $0.53 million for the quarter. Cogent Biosciences had a negative net margin of 96.84% and a negative return on equity of 87.78%.
View Cogent Biosciences' earnings history.

4 equities research analysts have issued 1-year target prices for Cogent Biosciences' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Cogent Biosciences' stock price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 59.2%.
View analysts' price targets for Cogent Biosciences.

Some companies that are related to Cogent Biosciences include Stoke Therapeutics (STOK), NGM Biopharmaceuticals (NGM), Revance Therapeutics (RVNC), Heron Therapeutics (HRTX), Keros Therapeutics (KROS), CytoDyn (CYDY), Zealand Pharma A/S (ZEAL), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Ligand Pharmaceuticals (LGND), MacroGenics (MGNX), Phathom Pharmaceuticals (PHAT), Kiniksa Pharmaceuticals (KNSA), Ocular Therapeutix (OCUL) and Karyopharm Therapeutics (KPTI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Cannabics Pharmaceuticals (CNBX), KushCo (KSHB), Novan (NOVN), Aeterna Zentaris (AEZS) and Zosano Pharma (ZSAN).

(UMRX) raised $75 million in an initial public offering (IPO) on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

Cogent Biosciences trades on the NASDAQ under the ticker symbol "UMRX."

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of UMRX stock can currently be purchased for approximately $9.81.

Cogent Biosciences has a market capitalization of $416.62 million and generates $22.50 million in revenue each year. The company earns $-31,830,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Cogent Biosciences employs 72 workers across the globe.

The official website for Cogent Biosciences is www.unumrx.com.

Cogent Biosciences' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at (617) 945-5576 or via email at [email protected]